Prostate cancer vaccine (GVAX) is an allogeneic vaccination strategy in which prostate cancer cells are genetically engineered to secrete high levels of GM-CSF, then mixed with autologous patient mononuclear cells ex vivo and reinfused. The gene discussed is CSF2; the disease is prostate carcinoma.